Vera Therapeutics, Inc.
Formerly CDF Therapeutics, Inc., Trucode Gene Repair, Inc.
Vera Therapeutics, Inc. is listed today as Vera Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2020 | $71 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Vera Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).
SEC Form D · Feb 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2021
That is all the official record says: Vera Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Vera Therapeutics, Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Abingworth LLP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Ares Trading S.A. | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Longitude Capital Partners IV, LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Longitude Venture Partners IV, L.P. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Merck Serono S.A. | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Sofinnova Management X, L.L.C. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Sofinnova Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 23 investors.
Largest shareholders today
Institutions holding Vera Therapeutics, Inc. shares, as of Sep 30, 2026.
- Deep Track Capital, LP$226 M9.68%
- BlackRock, Inc.$185 M7.92%
- Avoro Capital Advisors LLC$182 M7.79%
- Deerfield Management Company, L.P.$140 M6.00%
- State Street Corp$107 M4.57%
- Kynam Capital Management, LP$97 M4.15%
- Sofinnova Investments, Inc.$90 M3.86%
- FMR LLC$90 M3.86%
- Price T Rowe Associates Inc /MD/$89 M3.81%
- Vanguard Capital Management LLC$88 M3.75%
- Eversept Partners, LP$76 M3.27%
- Deutsche Bank AG\$69 M2.95%
- First Light Asset Management, LLC$63 M2.71%
- Frontier Capital Management Co LLC$61 M2.61%
- Pictet Asset Management Holding SA$59 M2.54%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Marshall Fordyce | Executive officer | Feb 2021 |
| Andrew Cheng | Director | Feb 2021 |
| Beth Seidenberg | Director | Feb 2021 |
| Kurt von Emster | Director | Feb 2021 |
| Maha Katabi | Director | Feb 2021 |
| Marshall Fordyce | Director | Feb 2021 |
| Patrick Enright | Director | Feb 2021 |
| Scott Morrison | Director | Feb 2021 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.